by Max Planck Society Erythropoietin (Epo) is actually a medication for anemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against COVID-19. The growth factor could mitigate severe disease progression and protect patients from long-term neurological effects when the SARS-CoV-2 virus attacks...
